


DIVI'S LABORATORIES LIMITED

**UNAUDITED FINANCIAL RESULTS (STANDALONE)
FOR THE QUARTER ENDED 30TH JUNE, 2015**

(₹ in Lakhs)


Sl No.	Particulars	STANDALONE			
		Unaudited			Audited
		Quarter ended 30.06.2015	Quarter ended 31.03.2015	Quarter ended 30.06.2014	Year Ended 31.03.2015
(1)	(2)	(3)	(4)	(5)	
1	Income from operations				
	(a) Net Sales/Income from operations (Net of Excise Duty)	80691	81469	63976	307230
	(b) Other Operating Income	185	240	290	1171
	Total Income from operations (net)	80876	81709	64266	308401
2	Expenditure:				
	a. Cost of materials consumed	35567	39186	29672	144627
	b. Purchases of stock-in-trade	0	0	0	0
	c. Changes in inventories of finished goods, work-in-progress and stock-in-trade	(3513)	(9457)	(4778)	(23083)
	d. Employee benefits expense	8033	7890	6018	28315
	e. Depreciation and amortization expense	2892	4454	3326	13585
	f. Other Expenses	10804	12578	9837	42337
	Total Expenses	53783	54651	44075	205781
3	Profit from Operations before Other Income, Interest & Exceptional Items (1-2)	27093	27058	20191	102620
4	Other Income	3399	1254	1269	4284
5	Profit from ordinary activities before finance costs & exceptional Items (3+4)	30492	28312	21460	106904
6	Finance Costs	22	59	36	186
7	Profit from ordinary activities after finance costs but before exceptional Items (5-6)	30470	28253	21424	106718
8	Exceptional items	0	0	0	0
9	Profit from ordinary activities before Tax (7-8)	30470	28253	21424	106718
10	Tax Expense:	6152	5362	4631	22012



11	Net Profit from ordinary activities after Tax: (9-10)	24318	22891	16793	84706
12	Extra-ordinary items (net of tax expense)	0	0	0	0
13	Net Profit (+)/Loss(-) for the period (11-12)	24318	22891	16793	84706
14	Share of profit / (loss) of associates	0	0	0	0
15	Minority Interest	0	0	0	0
16	Net Profit (+)/Loss(-) after taxes, minority interest and share of profit/ (loss) of associates (13+14+15)	24318	22891	16793	84706
17	Paid-up Equity Share Capital (Face Value : ₹. 2 per share)	2655	2655	2655	2655
18	Reserves excluding revaluation reserves as per balance sheet of previous accounting year				353541
19.i	Earnings per Share (before extraordinary items) (of ₹. 2/- each) (not annualized):				
	a) Basic	18.32	17.25	12.65	63.82
	b) Diluted	18.32	17.25	12.65	63.82
19.ii	Earnings per Share (after extraordinary items) (of ₹. 2/- each) (not annualized):				
	a) Basic	18.32	17.25	12.65	63.82
	b) Diluted	18.32	17.25	12.65	63.82

A	PARTICULARS OF SHAREHOLDING				
1	Public shareholding				
	- No. of shares	63603674	63603674	63603674	63603674
	- Percentage of shareholding	47.92%	47.92%	47.92%	47.92%
2	Promoters and promoter group shareholding:				
	a) pledged / encumbered	Nil	Nil	Nil	Nil
	b) non-encumbered:				
	No. of shares	69130616	69130616	69130616	69130616
	Percentage of shares (as a % of the total shareholding of the promoter group)	100%	100%	100%	100%
	Percentage of shares (as a % of the total share capital of the company)	52.08%	52.08%	52.08%	52.08%

	Particulars	Quarter ended 30th June 2015
B	INVESTOR COMPLAINTS	
	Pending at the beginning of the quarter	Nil
	Received during the quarter	8
	Disposed off during the quarter	8
	Remaining unresolved at the end of the quarter	Nil



NOTES:


1. The above results for the quarter ended 30th June 2015, as reviewed by the Audit Committee, were considered and approved by the Board of Directors at its meeting held on 8th August, 2015 and were subjected to 'limited review' by the Auditors.
2. The Company is primarily engaged in the manufacture of Active Pharmaceutical Ingredients and intermediates. Accordingly there are no reportable segments as per Accounting Standard 17 notified under the Companies Act, 1956.
3. As per Clause 41 of the listing agreement, the company has opted to publish quarterly unaudited standalone results and to publish consolidated results at the year end.
4. Details of forex gain/loss are given below:

	Quarter ended 30.06.2015	Quarter ended 31.03.2015	Quarter ended 30.06.2014	Year Ended 31.03.2015
	₹. Lakhs	₹. Lakhs	₹. Lakhs	₹. Lakhs
Forex gain/(loss)	2122	(1787)	135	(105)


Forex gain has been included in Other Income and forex loss has been included in Other Expenses.

5. Figures for the previous year/period have been regrouped wherever necessary.
6. Figures in respect of the results for preceding quarter ended 31st March, 2015 are the balancing figures between audited figures in respect of the financial year ended 31st March, 2015 and the published year-to-date figures upto the third quarter ended 31st December, 2014.
7. On the eve of 25th year of formation of the company, the Board is pleased to recommend issue of Bonus equity shares in the ratio of 1:1 i.e., one (1) equity share for every one (1) equity share held, subject to approval by the members of the company.

Place: Hyderabad
Date: 8th August, 2015



for Divi's Laboratories Limited


Dr. Mural K. Divi
Chairman & Managing Director

DIVI'S LABORATORIES LIMITED

CIN No.L24110TG1990PLC011854

**Divi Towers, Dharam Karan Road
Hyderabad 500 016**

Phone: 23786300 email: kishore@divislaboratories.com

PRESS RELEASE dated 8th August, 2015


Divi's Labs earns a total income of Rs. 809 crores for Q1 of FY16

Divi's Laboratories has earned a total income of Rs.809 crores for the 1st quarter of the year 2015-16 on a standalone basis, as against an income of Rs.643 crores for the corresponding quarter of last year, reflecting a growth of 26%.

The company earned a Profit after Tax (PAT) of Rs.243 crores for the current quarter. PAT for the corresponding quarter of the last year was Rs.168 crores, a growth of 45% over the corresponding quarter of last year.

Forex translation gain for the current quarter amounted to Rs. 21 crore as against a gain of Rs. 1 crore during the corresponding quarter of the last year.

On the eve of 25th year of formation of the company, the Board is pleased to recommend issue of Bonus equity shares in the ratio of 1:1 i.e., one (1) equity share for every one (1) equity share held, subject to approval by the members of the company.





P.V.R.K. Nageswara Rao & Co.,
Chartered Accountants

LIMITED REVIEW REPORT

**TO
THE BOARD OF DIRECTORS OF
DIVI' S LABORATORIES LIMITED**


We have reviewed the accompanying statement of unaudited financial results of **DIVI' S LABORATORIES LIMITED** for the quarter ended **30th June, 2015** except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' which have been traced from disclosures made by the management and have not been audited by us. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors / Committee of Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with the accounting standards issued under the Companies (Accounting Standard) Rules, 2006 which continue to apply as per Section 133 of the Companies Act, 2013, read with Rule 7 of the Companies (Accounts) Rules, 2014, and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement including the manner in which it is to be disclosed, or that it contains any material misstatement.

**For P.V.R.K. NAGESWARA RAO & Co.,
Chartered Accountants
Firm's Registration Number: 002283S**


**N. ANKA RAO
Partner
Membership Number: 23939**



**HYDERABAD
08.08.2015**